Spots Global Cancer Trial Database for Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Official Title: Prospective Registry of Iclusig® (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Study ID: NCT03678454
Interventions
Study Description
Brief Summary: This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ZNA Stuyvenberg, Antwerpen, , Belgium
UZ Antwerpen, Antwerpen, , Belgium
AZ Klina, Brasschaat, , Belgium
AZ St-Jan Brugge, Brugge, , Belgium
Institut Jules Bordet, Brussels, , Belgium
CHU Brugmann, Brussels, , Belgium
Hopital Erasme, Brussels, , Belgium
UZ Brussel, Brussels, , Belgium
Clinique universitaires Saint-Luc, Brussels, , Belgium
Ziekenhuis Oost Limburg (ZOL), Gent, , Belgium
Hopital Jolimont, Haine-Saint-Paul, , Belgium
Jessa Ziekenhuis, Hasselt, , Belgium
AZ Groeninge, Kortrijk, , Belgium
UZ Leuven, Leuven, , Belgium
CHU Sart Tilman Liège, Liège, , Belgium
CHU Charleroi Vésale, Montigny-le-Tilleul, , Belgium
AZ Turnhout St-Elisabeth, Turnhout, , Belgium
CHR La Tourelle, Verviers, , Belgium
CHU/UCL Namur Mont-Godinne, Yvoir, , Belgium
Contact Details
Name: Michael Beck, PhD
Affiliation: Incyte Biosciences Benelux
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
